Abstract
Elevated levels of plasminogen activator inhibitor-1 (PAI-1) are associated with poor prognosis in cancer. An explanation to the elevated levels of PAI-1 could be a protective response to the increased proteolytic activity, caused by elevated levels of urokinase-type plasminogen activator (uPA) observed in tumours; however, several lines of evidence suggest that PAI-1 may contribute directly to the pathology of the disease. PAI-1 has been reported to have an effect on most of the basic cellular processes including cell adhesion, cell migration, cell invasion, and cell proliferation and increasing numbers of reports suggest that PAI-1 also can regulate programmed cell death (PCD) in cancer cells and normal cells. A number of reports suggest that PAI-1 can inhibit PCD through its pro-adhesive/anti-proteolytic property whereas other reports suggest that PAI-1 induces PCD through its anti-adhesive property. Furthermore, it has been suggested that PAI-1 can either induce or inhibit PCD though activation of cell signalling pathways. This review will focus on the regulation of programmed cell death by PAI-1 in both normal cells and cancer cells.
Citations
Dec 17, 2009·Archives of Dermatological Research·Qiangguo GaoTian Yang
Dec 17, 2009·Apoptosis : an International Journal on Programmed Cell Death·Yiping LimDanny C F Wong
Jan 25, 2011·Oncogene·T P CashM C Simon
Sep 18, 2012·Journal of the National Cancer Institute·Hua FangYves A DeClerck
Feb 7, 2012·American Journal of Physiology. Heart and Circulatory Physiology·Paul D DiMustoGilbert R Upchurch
May 31, 2011·American Journal of Physiology. Lung Cellular and Molecular Physiology·Jaroslaw W ZmijewskiEdward Abraham
Aug 20, 2011·American Journal of Respiratory Cell and Molecular Biology·Wen-Tan HuangRui-Ming Liu
Mar 18, 2011·Molecular Cancer·Florian JantscherHedwig Sutterluety
Jun 10, 2011·Virology Journal·Olivier TerrierManuel Rosa-Calatrava
May 9, 2012·PloS One·Rym AbderrahmaniFabien Milliat
Aug 28, 2015·Translational Oncology·Rosa DivellaAntonio Mazzocca
Jun 22, 2010·Cancer·Markus BeckerSüleyman Ergün
Aug 26, 2010·Cancer·Esther C de HaasJourik A Gietema
Aug 27, 2010·Journal of Surgical Oncology·B MärklH Spatz
Oct 2, 2012·Thrombosis Research·Yan-Ping ZhangShu-Xia Song
Mar 28, 2012·Chemico-biological Interactions·Che-Jen HsiaoChi-Li Chung
May 3, 2014·Cancer Cell International·Xu WangYangqiu Li
Apr 28, 2012·PloS One·Meifan ChenZe'ev A Ronai
Jul 25, 2015·PloS One·Veronica R PlacencioYves A DeClerck
Jun 5, 2012·Acta Pharmacologica Sinica·Yan-ping ZhangMin Zhang
Feb 5, 2014·Critical Reviews in Clinical Laboratory Sciences·Julia DornViktor Magdolen
Sep 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carla Boccaccio, Paolo M Comoglio
Jul 8, 2016·Oncotarget·Miguel Angel PavónRamón Mangues